CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-12 | Atlas Venture Fund X, L.P. 10% owner | Sale 10b5-1 | −26,452 | $41.94 | $1.1M | 854,814 |
| 2024-03-12 | Atlas Venture Fund X, L.P. 10% owner | Sale 10b5-1 | −1,819 | $42.52 | $77K | 852,995 |
| 2024-03-12 | Booth Bruce Director | Sale 10b5-1 | −126,066 | $41.94 | $5.3M | 4,799,746 |
| 2024-03-12 | Booth Bruce Director | Sale 10b5-1 | −8,581 | $42.52 | $365K | 4,791,165 |
| 2024-03-12 | Booth Bruce Director | Sale 10b5-1 | −26,452 | $41.94 | $1.1M | 854,814 |
| 2024-03-12 | Booth Bruce Director | Sale 10b5-1 | −1,819 | $42.52 | $77K | 852,995 |
| 2024-03-11 | Atlas Venture Fund X, L.P. 10% owner | Sale 10b5-1 | −37,180 | $42.77 | $1.6M | 4,930,934 |
| 2024-03-11 | Atlas Venture Fund X, L.P. 10% owner | Sale 10b5-1 | −5,122 | $43.42 | $222K | 4,925,812 |
| 2024-03-11 | Atlas Venture Fund X, L.P. 10% owner | Sale 10b5-1 | −7,837 | $42.77 | $335K | 882,311 |
| 2024-03-11 | Atlas Venture Fund X, L.P. 10% owner | Sale 10b5-1 | −1,045 | $43.42 | $45K | 881,266 |
| 2024-03-11 | Booth Bruce Director | Sale 10b5-1 | −37,180 | $42.77 | $1.6M | 4,930,934 |
| 2024-03-11 | Booth Bruce Director | Sale 10b5-1 | −5,122 | $43.42 | $222K | 4,925,812 |
| 2024-03-11 | Booth Bruce Director | Sale 10b5-1 | −7,837 | $42.77 | $335K | 882,311 |
| 2024-03-11 | Booth Bruce Director | Sale 10b5-1 | −1,045 | $43.42 | $45K | 881,266 |
| 2024-03-04 | Gollob Jared Chief Medical Officer | Sale | −2,022 | $41.41 | $84K | 97,062 |
| 2024-03-04 | Gollob Jared Chief Medical Officer | Sale | −1,106 | $42.39 | $47K | 95,956 |
| 2024-03-04 | Gollob Jared Chief Medical Officer | Sale | −216 | $43.26 | $9K | 95,740 |
| 2024-03-04 | Jacobs Bruce N. Chief Financial Officer | Sale | −2,378 | $41.41 | $98K | 143,907 |
| 2024-03-04 | Jacobs Bruce N. Chief Financial Officer | Sale | −1,301 | $42.39 | $55K | 142,606 |
| 2024-03-04 | Jacobs Bruce N. Chief Financial Officer | Sale | −255 | $43.26 | $11K | 142,351 |
Page 29 of 41 · 810 trades